A pilot study of immunorespons in children with Down syndrome after Respiratory Syncytial Virus (RSV) lower respiratory tract infections (LRTI)

Completed

• Conditions: Down syndrome; Mongols; Immunodeficiency; physical defense disorder; Trisomy 21; 10083624; 10027665; 10047438

• Registration Number: NL-OMON31485
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 12 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

Down syndrome, age 0-12 years; healthy matched-controls

Exclusion Criteria

Bronchopulmonary dysplasia, prematurity (gestational age <37 weeks ), hemodynamic significant congenital heart disease, immunodeficiencys, current infectious disease, fever in month before inclusion

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome is the difference in immunorespons after RSV LRTI in<br /><br>children with DS and 'healthy' peers. The difference will be stated upon: RSV<br /><br>specific cytokine production; total number of T-cells, B-cells, Antigen<br /><br>Presenting Cells, Natural Killer cells and Dendritic cells; general cytokine<br /><br>expression.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Age, sex and ethnic background will be taken into account as variables in the<br /><br>analyses.</p><br>